AI
Wednesday, October 13, 2010 12:32:01 PM
LGND:
They should be cash flow positive next year. Beyond that (in the next couple years) it is a bet on Promacta sales ramping (and GSK advancing 2nd generation compounds). I think the Hep C results 2H next year have a lot less risk now (we should be nearing the end of treatment for most patients over the next couple months) but I am not sure how much that'll help sales.
They had some compounds killed lately and don't have any near term great royalty ops (outside of Promacta) but I really like the business model and Higgins has an economics background so hopefully he realizes the value of a buck
They should be cash flow positive next year. Beyond that (in the next couple years) it is a bet on Promacta sales ramping (and GSK advancing 2nd generation compounds). I think the Hep C results 2H next year have a lot less risk now (we should be nearing the end of treatment for most patients over the next couple months) but I am not sure how much that'll help sales.
They had some compounds killed lately and don't have any near term great royalty ops (outside of Promacta) but I really like the business model and Higgins has an economics background so hopefully he realizes the value of a buck
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
